Radiotargeting agents for cancer therapy

Expert Opinion on Drug Delivery

Volumn 2, Issue 6, 2005, Pages 981-991

  Kassis, Amin I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

particle emitter; particle emitter; Auger electron emitter; Radiobiology; Radionuclide therapy

Indexed keywords

ACTINIUM; ACTINIUM 225; ASTATINE 211; BISMUTH 212; BISMUTH 213; BROMINE 77; COPPER 67; DEOXYURIDINE; DNA; DRUG CARRIER; IDOXURIDINE; INDIUM 111; IODINE 123; IODINE 125; LIGAND; METHOTREXATE; MONOCLONAL ANTIBODY; OXYGEN; PHOSPHORUS 32; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM; RADIUM 223; RHENIUM 186; RHENIUM 188; SODIUM CHLORIDE; STRONTIUM 89; TELLURIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ALPHA RADIATION; AUGER ELECTRON SPECTROSCOPY; BEAM THERAPY; BETA RADIATION; BRACHYTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; DRUG HALF LIFE; DRUG TARGETING; ELECTRON THERAPY; LINEAR ENERGY TRANSFER; MALIGNANT NEOPLASTIC DISEASE; MAMMAL CELL; NONHUMAN; PARTICLE RADIATION; PHOTON; RADIATION DOSE; RADIOBIOLOGY; RADIOISOTOPE DECAY; RADIOISOTOPE DISTRIBUTION; RADIOISOTOPE THERAPY; RADIOSENSITIZATION; REVIEW;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DNA; DOSE-RESPONSE RELATIONSHIP, RADIATION; HALF-LIFE; HUMANS; NEOPLASMS; RADIOBIOLOGY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE;

EID: 28244470314     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.6.981     Document Type: Review

References (42)

1. WALICKA MA, VAIDYANATHAN G, ZALUTSKY MR, ADELSTEIN SJ, KASSIS AI: Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat. Res. (1998) 150:263-268.
2. GODDU SM, HOWELL RW, RAO DV: Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J. Nucl. Med. (1994) 35:303-316.
3. SASTRY KSR, HOWELL RW, RAO DV et al.: Dosimetry of Auger emitters: physical and phenomenological approaches. In: DNA Damage by Auger Emitters. KF Baverstock, DE Charlton (Eds.), Taylor and Francis, London, UK (1988):27-38.
4. WRIGHT HA, HAMM RN, TURNER JE, HOWELL RW, RAO DV, SASTRY KS: Calculations of physical and chemical reactions with DNA in aqueous solution from Auger cascades. Radiat. Prot. Dosim. (1990) 31:59-62.
5. 35S: theory and application to a cellular model. Radiat. Res. (1980) 84:407-425.
6. KASSIS AI, ADELSTEIN SJ, HAYDOCK C, SASTRY KS, MCELVANY KD, WELCH MJ: Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat. Res. (1982) 90:362-373.
7. KASSIS AI, SASTRY KS, ADELSTEIN SJ: Intracellular localisation of Auger electron emitters: biophysical dosimetry. Radiat. Prot. Dosim. (1985) 13:233-236.
8. XUE LY, BUTLER NJ, MAKRIGIORGOS GM, ADELSTEIN SJ, KASSIS AI: Bystander effect produced by radiolabeled tumor cells in vivo. Proc. Natl. Acad. Sci. USA (2002) 99:13765-13770.
9. HUMM JL, CHIN LM, COBB L, BEGENT R: Microdosimetry in radioimmunotherapy. Radiat. Prot. Dosim. (1990) 31:433-436.
10. ICRU: Absorbed-dose specification in nuclear medicine (ICRU Report 67). J. ICRU (2002) 2(1):1-110.
11. O'DONOGHUE JA: The impact of tumor cell proliferation in radioimmunotherapy. Cancer (1994) 73:974-980.
12. JAIN RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. (1990) 50 (Suppl. 3):814s-819s.
13. NETTI PA, HAMBERG LM, BABICH JW et al.: Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA (1999) 96:3137-3142.
14. KASSIS AI, HARRIS CR, ADELSTEIN SJ, RUTH TJ, LAMBRECHT R, WOLF AP: The in vitro radiobiology of astatine-211 decay. Radiat. Res. (1986) 105:27-36.
15. 212Bi distributed in the growth medium. Radiat. Prot. Dosim. (1994) 52:311-315.
16. 90Y. Int. J. Radiat. Oncol. Biol. Phys. (1984) 10:341-348.
17. MACKLIS RM, KINSEY BM, KASSIS AI et al.: Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science (1988) 240:1024-1026.
18. ZALUTSKY MR, MCLENDON RE, GARG PK, ARCHER GE, SCHUSTER JM, BIGNER DD: Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res. (1994) 54:4719-4725.
19. MCDEVITT MR, MA D, LAI LT et al.: Tumor therapy with targeted atomic nanogenerators. Science (2001) 294:1537-1540.
20. 3HTdR. Radiat. Res. (1976) 67:332-343.
21. 3H disintegration in the DNA of Chinese hamster cells. Curr. Top. Radiat. Res. Q. (1977) 12:408-425.
22. ESTEBAN JM, SCHLOM J, MORNEX F, COLCHER D: Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs. Eur. J. Cancer Clin. Oncol. (1987) 23:643-655.
23. OTTE A, MUELLER-BRAND J, DELLAS S, NITZSCHE EU, HERRMANN R, MAECKE HR: Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet (1998) 351:417-418.
24. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int. J. Oncol. (1999) 15:1017-1025.
25. AXWORTHY DB, RENO JM, HYLARIDES MD et al.: Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA (2000) 97:1802-1807.
26. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). Clin. Cancer Res. (1997) 3:71-79.
27. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. (1993) 329:459-465.
28. WITZIG TE: Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (2004) 40:111-119.
29. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. (2005) 352:441-449.
30. KASSIS AI, ADELSTEIN SJ, HAYDOCK C, SASTRY KS: Thallium-201: an experimental and a theoretical radiobiological approach to dosimetry. J. Nucl. Med. (1983) 24:1164-1175.
31. KASSIS AI, SASTRY KS, ADELSTEIN SJ: Intracellular distribution and radiotoxicity of chromium-51 in mammalian cells: Auger-electron dosimetry. J. Nucl. Med. (1985) 26:59-67.
32. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat. Res. (1987) 109:78-89.
33. 125I in mammalian cells. Radiat. Res. (1987) 111:305-318.
34. 123I: the use of the Auger effect as a biological probe at the nanometre level. Radiat. Prot. Dosim. (1990) 31:333-338.
35. 131iodine. Radiat. Res. (1971) 47:94-109.
36. BLOOMER WD, MCLAUGHLIN WH, WEICHSELBAUM RR et al.: Iodine-125-labelled tamoxifen is differentially cytotoxic to cells containing oestrogen receptors. Int. J. Radiat. Biol. (1980) 38:197-202.
37. 125I]iodoHoechst 33342: contribution of scavengeable effects. Int. J. Radiat. Biol. (1999) 75:1579-1587.
38. 3H: nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia. Int. J. Radiat. Biol. (1975) 28:225-241.
39. 125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature (1977) 265:620-621.
40. 123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. Int. J. Radiat. Oncol. Biol. Phys. (1991) 21:1541-1551.
41. 125I]iodo-2′-deoxyuridine. Acta Oncol. (2000) 39:731-737.
42. 125I]iodo-2′-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. Int. J. Radiat. Biol. (2004) 80:941-946.